The DOI matches its Crossref record.
Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends
Abstract
Hepatitis C Virus (HCV) infection appears to be endemic in most parts of the world, with an estimated overall prevalence of 3%. However, there is considerable geographic and temporal variation in the incidence and prevalence of HCV infection. Using age-specific prevalence data, at least three distinct transmission patterns can be identified. In countries with the first pattern (e.g., United States, Australia), most infections are found among persons 30-49 years old, indicating that the risk for HCV infection was greatest in the relatively recent past (10-30 years ago) and primarily affected young adults. In countries with the second pattern (e.g., Japan, Italy), most infections are found among older persons, consistent with the risk for HCV infection having been greatest in the distant past. In countries with the third pattern (e.g., Egypt), high rates of infection are observed in all age groups, indicating an ongoing high risk for acquiring HCV infection. In countries with the first pattern, injection drug use has been the predominant risk factor for HCV infection, whereas in those with the second or third patterns, unsafe injections and contaminated equipment used in healthcare-related procedures appear to have played a predominant role in transmission. Much of the variability between regions can be explained by the frequency and extent to which different risk factors have contributed to the transmission of HCV. Because different strategies are required to interrupt different patterns of HCV transmission, determining the epidemiology of HCV infection in areas where that information has not yet been assessed is critical for developing appropriate prevention programs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Global patterns of cancer incidence and mortality rates and trends
Jemal, A., Center, M. M., DeSantis, C., & Ward, E. M. (2010) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0437 · Cited by 2,778
Global epidemiology of hepatitis C virus infection
Shepard, C. W., Finelli, L., & Alter, M. J. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70216-4 · Cited by 2,758
Self-citationPerz, J. F., Armstrong, G. L., Farrington, L. A., Hutin, Y. J. F., & Bell, B. P. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.05.013 · Cited by 2,572
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Poordad, F., McCone, J., Bacon, B. R., Bruno, S., Manns, M. P., Sulkowski, M. S., Jacobson, I. M., Reddy, K. R., Goodman, Z. D., Boparai, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010494 · Cited by 2,520
Mohd Hanafiah, K., Groeger, J., Flaxman, A. D., & Wiersma, S. T. (2013) · Hepatology · doi:10.1002/hep.26141 · Cited by 2,515
Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis
de Martel, C., Georges, D., Bray, F., Ferlay, J., & Clifford, G. M. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(19)30488-7 · Cited by 2,475
The global burden of hepatitis C
Lavanchy, D. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01934.x · Cited by 1,368
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus
Scarselli, E., Ansuini, H., Cerino, R., Roccasecca, R. M., Acali, S., Filocamo, G., Traboni, C., Nicosia, A., Cortese, R., & Vitelli, A. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf529 · Cited by 1,177
Epidemiology of Hepatocellular Carcinoma
Bosch, F. X., Ribes, J., Cléries, R., & Díaz, M. (2005) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.12.009 · Cited by 1,131
Epidemiology of viral hepatitis and HIV co-infection
Alter, M. J. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.11.004 · Cited by 1,012
Self-citationEpidemiology and natural history of HCV infection
Hajarizadeh, B., Grebely, J., & Dore, G. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.107 · Cited by 994
Micallef, J. M., Kaldor, J. M., & Dore, G. J. (2006) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2005.00651.x · Cited by 871
Genetic diversity and evolution of hepatitis C virus – 15 years on
Simmonds, P. (2004) · Journal of General Virology · doi:10.1099/vir.0.80401-0 · Cited by 865
The Natural History of Hepatitis C Virus (HCV) Infection
Chen, S. L., & Morgan, T. R. (2006) · International Journal of Medical Sciences · doi:10.7150/ijms.3.47 · Cited by 860
Lee, M.-H., Yang, H.-I., Lu, S.-N., Jen, C.-L., You, S.-L., Wang, L.-Y., Wang, C.-H., Chen, W. J., Chen, C.-J., & for the R.E.V.E.A.L.-HCV Study Group (2012) · Journal of Infectious Diseases · doi:10.1093/infdis/jis385 · Cited by 554
A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt
Sievert, W., Altraif, I., Razavi, H. A., Abdo, A., Ahmed, E. A., AlOmair, A., Amarapurkar, D., Chen, C., Dou, X., El Khayat, H., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02540.x · Cited by 534
Radziewicz, H., Ibegbu, C. C., Fernandez, M. L., Workowski, K. A., Obideen, K., Wehbi, M., Hanson, H. L., Steinberg, J. P., Masopust, D., Wherry, E. J., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02021-06 · Cited by 483
The changing epidemiology of hepatitis C virus infection in Europe
Esteban, J. I., Sauleda, S., & Quer, J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.07.033 · Cited by 481
Peginterferon and Ribavirin for Chronic Hepatitis C
Hoofnagle, J. H., & Seeff, L. B. (2006) · New England Journal of Medicine · doi:10.1056/nejmct061675 · Cited by 476
The global burden of disease attributable to contaminated injections given in health care settings
Hauri, A. M., Armstrong, G. L., & Hutin, Y. J. F. (2004) · International Journal of STD & AIDS · doi:10.1258/095646204322637182 · Cited by 458
The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis
Mohamoud, Y. A., Mumtaz, G. R., Riome, S., Miller, D., & Abu-Raddad, L. J. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-288 · Cited by 413
Challenges and successes in developing new therapies for hepatitis C
De Francesco, R., & Migliaccio, G. (2005) · Nature · doi:10.1038/nature04080 · Cited by 411
Perni, R. B., Almquist, S. J., Byrn, R. A., Chandorkar, G., Chaturvedi, P. R., Courtney, L. F., Decker, C. J., Dinehart, K., Gates, C. A., Harbeson, S. L., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.899-909.2006 · Cited by 386
Ye, J., Wang, C., Sumpter, R., Brown, M. S., Goldstein, J. L., & Gale, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2237238100 · Cited by 366
Flying Under the Radar: The Immunobiology of Hepatitis C
Dustin, L. B., & Rice, C. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141602 · Cited by 313
Wang, C., Gale, M., Keller, B. C., Huang, H., Brown, M. S., Goldstein, J. L., & Ye, J. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.004 · Cited by 299
Interferon-Induced Depression in Chronic Hepatitis C: A Systematic Review and Meta-Analysis
Udina, M., Castellví, P., Moreno-España, J., Navinés, R., Valdés, M., Forns, X., Langohr, K., Solà, R., Vieta, E., & Martín-Santos, R. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r07694 · Cited by 297
In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061
Lin, C., Lin, K., Luong, Y.-P., Rao, B. G., Wei, Y.-Y., Brennan, D. L., Fulghum, J. R., Hsiao, H.-M., Ma, S., Maxwell, J. P., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313020200 · Cited by 288
The Progression of Liver Fibrosis Is Related with Overexpression of the miR-199 and 200 Families
Murakami, Y., Toyoda, H., Tanaka, M., Kuroda, M., Harada, Y., Matsuda, F., Tajima, A., Kosaka, N., Ochiya, T., & Shimotohno, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016081 · Cited by 282
Venkatraman, S., Bogen, S. L., Arasappan, A., Bennett, F., Chen, K., Jao, E., Liu, Y.-T., Lovey, R., Hendrata, S., Huang, Y., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060325b · Cited by 281
Trends in mortality from hepatocellular carcinoma in Europe, 1980‐2004†
Bosetti, C., Levi, F., Boffetta, P., Lucchini, F., Negri, E., & La Vecchia, C. (2008) · Hepatology · doi:10.1002/hep.22312 · Cited by 280
Heffernan, A., Cooke, G. S., Nayagam, S., Thursz, M., & Hallett, T. B. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32277-3 · Cited by 265
Sarasin, F. P., Majno, P. E., Llovet, J. M., Bruix, J., Mentha, G., & Hadengue, A. (2001) · Hepatology · doi:10.1053/jhep.2001.23311 · Cited by 263
Rauch, A., Martin, M., Weber, R., Hirschel, B., Tarr, P. E., Bucher, H. C., Vernazza, P., Bernasconi, E., Zinkernagel, A. S., Evison, J., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/431486 · Cited by 210
“The possibility of HCV transmission by sharing materials used for intranasal cocaine use remains controversial [27–29].”
BackgroundKato, J., Miyanishi, K., Kobune, M., Nakamura, T., Takada, K., Takimoto, R., Kawano, Y., Takahashi, S., Takahashi, M., Sato, Y., et al. (2007) · Journal of Gastroenterology · doi:10.1007/s00535-007-2095-z · Cited by 172
Global epidemiology and burden of hepatitis C
Ray Kim, W. (2002) · Microbes and Infection · doi:10.1016/s1286-4579(02)01649-0 · Cited by 149
Transplantation trends in primary biliary cirrhosis
Lee, J., Belanger, A., Doucette, J. T., Stanca, C., Friedman, S., & Bach, N. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.07.015 · Cited by 147
Bixler, D., Annambholta, P., Abara, W. E., Collier, M. G., Jones, J., Mixson-Hayden, T., Basavaraju, S. V., Ramachandran, S., Kamili, S., & Moorman, A. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15352 · Cited by 29
Metadata
- Authors
- Wasley, A., & Alter, M. J.
- Venue
- Seminars in Liver Disease
- Publisher
- Georg Thieme Verlag KG
- Published
- 2000
- Volume
- Volume 20
- Issue
- Number 01
- Pages
- 0001-0016
- ISSN
- 0272-8087 (ISSN-L)
- 1098-8971
- OpenAlex
- W2062395204
- Cited by
- 979
- References
- 0
- FWCI
- 23.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.